The Clinical Observation of Gemcitabine Combined with Cisplatin Regimen on Recurrent Triple-Negative Breast Cancer
Objective:To investigate the effect of gemcitabine combined with cisplatin regimen on patients with recurrent triple-negative breast cancer(TNBC)following anthracycline and taxoid drug treatment.Methods:81 patients with recurrent TNBC treated with anthracycline and paclitaxel drugs admitted to a certain hospital between January 2019 and January 2021 were selected as the study subjects.A randomized,single blind trial was conducted,and they were divided into group A(n=40)and group B(n=41)using a random number table method.Group A patients were treated with gemcitabine hydrochloride for injection combined with capecitabine tablets,while group B patients were treated with gemcitabine hydrochloride for injection combined with cisplatin for injection.Compare the clinical efficacy,changes in serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),carbohydrate antigen 125(CA125)]levels,quality of life[European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTC QLQ-C30)],incidence of adverse reactions,and prognosis of patients within 2 years after treatment between two groups.Results:After treatment,the total effective rate of treatment in group B(82.93%)was higher than that in group A(60.00%,P<0.05).The serum levels of CEA,CA153,and CA125 in both groups decreased(P<0.05),and group B was lower than group A(P<0.05).The EORTC QLQ-C30 scores of both groups decreased in fatigue and insomnia(P<0.05),and group B was lower than group A(P<0.05);The EORTC QLQ-C30 scores of both groups increased in overall health(P<0.05),and group B was higher than group A(P<0.05);There was no statistically significant difference in the EORTC QLQ-C30 scores between the two groups in terms of nausea,vomiting,loss of appetite,and constipation(P>0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients during treatment(P>0.05).The recurrence rate within 2 years in group B patients(14.63%)was lower than that in group A(40.00%,P<0.05),the median progression free survival(6.65±1.45)months was longer than that in group A(4.26±1.23)months(P<0.05),and the number of stable cases(58.54%)was higher than that in group A(30.00%,P<0.05).Conclusion:Compared with gemcitabine combined with capecitabine,the gemcitabine combined with cisplatin treatment regimen has better clinical efficacy in recurrent TNBC patients after anthracycline and paclitaxel treatment.It can effectively reduce the serum tumor marker levels of patients,improve quality of life,and improve prognosis.
gemcitabinecisplatinanthracene ringtaxanestriple-negative breast cancerrecurrence
万方数据
维普
